MVX-220

N/A

Report date: 2025/10/10 15:37:20

Base Information

Drug NameMVX-220
Drug Alias NameMVX-220
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionUbiquitin-like modifier-activating enzyme 3A modulators
TargetsUbiquitin-like modifier-activating enzyme 3A
Therapy Area/IndicationsAngelman Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMavriX Bio
China Registration ClassN/A

Develop Information

Active CompaniesMavriX Bio
Inactive CompaniesN/A
Active IndicationsAngelman Syndrome
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A